Rogocekib

N/A

Report date: 2025/05/13 16:53:26

NME

Base Information

Drug NameRogocekib

Drug Alias NameCTX-712

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionClk dual-specificity kinase inhibitorsDual-specificity tyrosine-phosphorylation regulated kinase 1A inhibitorsDual specificity tyrosine-phosphorylation-regulated kinase 1B inhibitors

TargetsDual specificity protein kinase CLKDual-specificity tyrosine-phosphorylation regulated kinase 1ADual specificity tyrosine-phosphorylation-regulated kinase 1B

Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, AcuteNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesJapan

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesTakeda Pharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesChordia Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, AcuteNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A